Canaccord Genuity Maintains Buy on Clover Health Investments, Lowers Price Target to $3.7
Benzinga Newsdesk 12 months ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst Richard Close maintains Clover Health Investments (NASDAQ:CLOV) with a Buy and lowers the price target from $4.1 to $3.7.
Canaccord Genuity analyst Richard Close maintains Clover Health Investments (NASDAQ:CLOV) with a Buy and lowers the price target from $4.1 to $3.7.